STOK
Stoke Therapeutics, Inc.
$29.11
-0.80 (-2.67%)
At close · Jul 16
Market Cap
$1.81B
Shares
62,281,655
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$184.42M
+404.5%
FY2025
Net Income
-$6.89M
+92.3%
FY2025
Operating Margin
-11.16%
+266.2pp
FY2025
Diluted EPS
-$0.12
+92.7%
FY2025
Operating Cash Flow
$45.59M
+152.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $32.08M | $184.42M | $36.56M | $8.78M | $12.41M | — | — | — | — | |
| $144.92M | $137.92M | $89.13M | $82.23M | $77.84M | $54.17M | $32.2M | $23.76M | $8.37M | |
| $55.45M | — | $48.79M | $41.32M | $38.92M | $31.9M | $20.85M | $11.91M | $4.41M | |
| — | $67.09M | $48.79M | — | — | — | — | — | — | |
| $217.33M | $205.01M | $137.93M | $123.55M | $116.76M | $86.07M | $53.04M | $35.68M | $12.78M | |
| -$185.25M | -$20.59M | -$101.37M | -$114.77M | -$104.36M | -$86.07M | -$53.04M | -$35.68M | -$12.78M | |
| — | -11.16% | -277.31% | -1307.21% | -841.24% | — | — | — | — | |
| $31K | $9000 | $26K | $49K | — | — | — | — | — | |
| $14.3M | $13.77M | $12.66M | $9.96M | — | — | $744K | $3.35M | $270K | |
| $14.2M | $13.71M | $12.39M | $10.07M | $3.29M | $260K | $801K | $3.35M | $260K | |
| -$1.28M | $0 | — | — | — | — | — | — | — | |
| -$169.77M | -$6.89M | -$88.98M | -$104.7M | -$101.07M | -$85.81M | -$52.24M | -$32.33M | -$12.52M | |
| — | -3.73% | -243.42% | -1192.47% | -814.73% | — | — | — | — | |
| -$169.78M | -$6.19M | -$89.11M | -$103.55M | -$102.07M | -$85.97M | -$52.24M | — | — | |
| USD/shares | — | -$0.12 | -$1.65 | -$2.38 | -$2.60 | -$2.34 | — | — | — |
| USD/shares | — | -$0.12 | -$1.65 | -$2.38 | -$2.60 | -$2.34 | — | — | — |
| shares | — | 59.22M | 54.01M | 43.99M | 38.9M | 36.74M | 33.49M | 17.97M | 709.34K |
| shares | — | 59.22M | 54.01M | 43.99M | 38.9M | 36.74M | 33.49M | 17.97M | 709.34K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.53×
EV/EBIT
—
Biotechnology median 26.49×
P/E (TTM)
—
Biotechnology median 7.39×